TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05902767

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nuts
Description: * A mix of nuts containing 1 Brazil nut (\~3g), walnuts (15g), hazelnuts (7g), and almonds (7g) to be consumed daily for 90 days.~* Dietary counselling on how to follow the Australian Dietary Guidelines

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: - Dietary counselling on how to follow the Australian Dietary Guidelines
Study: NCT06354959

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prehabilitation
Description: 8-week community based prehab program
Study: NCT05428059

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mobile education
Description: The training content prepared by the researchers will be presented to the expert opinion. After the necessary arrangements, it will be installed on the mobile application. The mobile application will be downloaded to the patients' phones for one month. It will be in live consultation.
Study: NCT05371587

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autonomy and Perceptions Approach to Resistance Training (APART)
Description: Alternative resistance training prescription based on trainees' autonomy and perceptions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard prescription
Description: Standard resistance training prescription, based on international organization's guidelines.
Study: NCT05813145

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 25 patients will receive four cycle of AC followed by paclitaxel 80 mg/m2 weekly for 12 week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fenofibrate 160mg
Description: 25 patients will receive four cycle of AC followed by paclitaxel 80 mg/m2 weekly for 12 week in addition to 160mg fenofibrate once daily for 3 month.
Study: NCT05913804

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: YTS104 Cells injection
Description: YTS104 Cell injection is a new STAR-T cell transfected by lentivirus.The study required that lymphocytes were collected from the subjects and cultured for 2-3 weeks to obtain YTS104 cell injection. Subjects were treated with fludarabine and cyclophosphamide chemotherapy prior to reinfusion, followed by a 2-day rest period before cell infusion.
Study: NCT04541381

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Availability of clinical decision support based on pharmacogenomic results.
Description: Availability of clinical decision support based on pharmacogenomic results. These results are designed to provide specific dosing information based on the participant's unique genetics/genomics.
Study: NCT05515523

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Adipose Derived (AD) Stromal Vascular Fraction (SVF)
Description: autologous stromal vascular fraction cells from adipose tissue for reintroduction to the same patient during a single surgical procedure for treatment of pain and function associated with OA of the knee joint
Study: NCT05919238

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Padeliporfin Vascular Targeted Photodynamic (VTP) therapy
Description: The laser light fiber with inflatable balloon to dam SMA blood flow during light illumination will be placed by an Interventional Radiologist in the SMA via a transfemoral artery approach. The balloon will be inflated to impede blood flow for total of 10 minutes during light illumination

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Padeliporfin Vascular Targeted Photodynamic (VTP) therapy
Description: The laser light fiber with inflatable balloon to dam SMA blood flow during light illumination will be placed by an Interventional Radiologist in the SMA via a transfemoral artery approach. The balloon will be inflated to impede blood flow for total of 10 minutes during light illumination
Study: NCT05975541

Intervention type: OTHER
Intervention: Observational
Description: No intervention will be carried out in this study. Patients from both groups will be monitored for 12 months through observations at time 0, time 6 months, and 12 months. Questionnaires, good clinical practice samples, and anthropometric measurements will be made to monitor changes in the two groups.

Intervention type: OTHER
Intervention: Observational
Description: No intervention will be carried out in this study. Patients from both groups will be monitored for 12 months through observations at time 0, time 6 months, and 12 months. Questionnaires, good clinical practice samples, and anthropometric measurements will be made to monitor changes in the two groups.
Study: NCT04992949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPX-351
Description: Induction : patients will receive induction treatment with CPX-351 100 U/m2 on days 1, 3, and 5. Patients who fail to achieve CR/CRi after the induction cycle will be offered a second induction course of CPX-351 100 U/m2 on days 1 and 3, at the investigators' discretion. If CR/CRi is not achieved following the second induction cycle, patients will go off study~Consolidation : patients in CR/CRi after induction cycle will receive up to 2 course of consolidation therapy with CPX-351 65 U/m2 on days 1 and 3. CPX351 doses could be reduced to 65 U/m2 on day 1 in case of unacceptable toxicity following the previous course.~Allo-SCT : patients for whom an allo-SCT is planned will receive a maximum of one consolidation cycle
Study: NCT05971212

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioural sleep clinic access
Description: Access to behavioural Sleep Clinic

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioural sleep clinic access
Description: Access to behavioural Sleep Clinic
Study: NCT04978857

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: autobiographic movie
Description: viewing an autobiographic film through a virtual reality headset
Study: NCT05615467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3556050
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iohexol
Description: Administered IV.
Study: NCT06105489

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lateral Sinus Lift using tunnel flap technique
Description: The surgical procedure will involve the following steps:~* A single vertical anterior incision will be made, at least 10 mm mesially to the expected outline of the bony window.~* A full-thickness flap will be carefully elevated to expose the lateral wall of the maxillary sinus.~* A trap door will be created in the lateral wall of the maxillary sinus using either a dedicated piezosurgical insert or a straight handpiece with a 3mm round diamond bur.~* The door will be removed.~* The sinus membrane will be gently elevated using various-shaped curettes until it becomes completely detached from the lateral, inferior, and medial walls of the sinus.~* The maxillary sinus will be filled with a heterologous bone graft with a well-documented efficacy.~* The flaps will be meticulously sutured.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lateral Sinus Lift using crestal incision flap
Description: The surgical procedure will involve the following steps:~* A horizontal incision is made on the top of the alveolar ridge, along with two additional releasing incisions in the mesial and distal regions.~* A full-thickness flap will be carefully elevated to expose the lateral wall of the maxillary sinus.~* A trap door will be created in the lateral wall of the maxillary sinus using either a dedicated piezosurgical insert or a straight handpiece with a 3mm round diamond bur.~* The door will be removed.~* The sinus membrane will be gently elevated using various-shaped curettes until it becomes completely detached from the lateral, inferior, and medial walls of the sinus.~* The maxillary sinus will be filled with a heterologous bone graft with a well-documented efficacy.~* The flaps will be meticulously sutured.
Study: NCT06535256

Intervention type: DRUG
Group type: OTHER
Intervention: bupivacaine with dexamethasone
Description: intra-peritoneal instillation of bupivacaine with dexamethasone (received 40 mL of 0.25% bupivacaine + 16 mg dexamethasone with 5 ml normal saline).

Intervention type: DRUG
Group type: OTHER
Intervention: bupivacaine with dexmedetomidine
Description: intra-peritoneal instillation of bupivacaine with dexmedetomidine (received 40 mL of 0.25% bupivacaine + dexmedetomidine 1 μg/kg with normal saline 5 ml).
Study: NCT06146569

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)
Description: Current will be applied bilaterally from the tragus and turbinate parts of the ear with the VagustimTM device. The current frequency to be used in modulation mode is 10 Hz, and the pulse width is 300 μs (In modulation mode, the pulse rate and width are automatically changed in a loop pattern. The pulse width is reduced by 50% from its original setting in 0.5 seconds; then, the pulse rate is changed in 0.5 seconds, reduced by 50% from the original setting. Total cycle time is 1 second.). The current intensity will be applied for 5 minutes, keeping the current constant where the participant feels comfortable.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)
Description: For 5 minutes, sham applications will be applied using a current-free headset specifically designed for this purpose. Participants will observe the device's functionality, but it will not supply any current.
Study: NCT05349422

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electronic Health Record (EHR) Enabled Teamlets
Description: The intervention consist of four components: 1) patients with hypertension will be automatically screened for low medication adherence using linked EHR-pharmacy data at the time of a PCP encounter; 2) MAs will deliver a validated, rapid, survey of common causes of non-adherence; 3) MAs and/or RNs will address barriers to adherence tailored to survey response, including delivery of brief health coaching based on motivational interviewing; and 4) PCPs will address specific barriers to adherence based on survey response.
Study: NCT06456294

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MHC Outreach Intervention
Description: Adult PC clinics are randomized to receive the MHC Outreach Intervention early (n=7 clinics) vs. delayed (n=7 clinics). In early intervention clinics, patients prescribed chronic opioid therapy, on a chronic opioid registry, and receiving their medication from the intervention clinic are sent emails and letters inviting them to schedule an MHC appointment. Clinical staff at the early intervention clinic are educated to encourage attendance. During MHC visits, MHC staff assess patients prescribed Chronic Opioid Therapy (COT), educate them about overdose, prescribe naloxone, and order guideline-concordant opioid monitoring.
Study: NCT04915859

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hand Cooling at 12-15 degrees celsius
Description: hand cooling at 12-15 degrees celsius will be performed for active cooling by having participants place their hands on the cooling device set to this temperature

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hand Cooling at 16-20 degrees celsius
Description: hand cooling at 16-20 degrees celsius will be performed for active cooling by having participants place their hands on the cooling device set to this temperature

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: hand and back cooling at 12-15 or 16-20 degrees celsius
Description: hand and back cooling at 12-15 or 16-20 degrees celsius will be performed for active cooling by having participants place their hands on the cooling device set to this temperature while also wearing the back wrap cooling device set to this temperature

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Passive cooling
Description: participants will sit in a chair and passively cool (no active intervention)
Study: NCT04840758

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Ablation Radiotherapy
Description: Stereotactic ablation radiotherapy was performed sequentially on the primary and secondary lesions. 50Gy/4F or 70Gy/10F were used according to the specific location of the tumor。

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab was started 2 weeks after the end of radiotherapy. Sintilimab : 200 mg intravenously, Q3W every cycle , given on the D1 of each cycle, and total of 4 cycles
Study: NCT05979792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAR-T Therapy
Description: CAR-T cell infusion
Study: NCT05067140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARV-766 Part A&B
Description: Part A: Daily oral dosages are determined by cohort review committee after initial starting dose cohort and each subsequent cohort completes 28 days of treatment.~Part B: Oral tablet(s) once daily in 28 day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARV-766 + Abiraterone Part C&D
Description: Part C: Daily oral combination dosages are determined by cohort review committee after initial starting dose cohort and each subsequent cohort completes 28 days of treatment.~Part D: Combination administered once daily in 28 day cycles.~Parts C\&D: Participants will also receive concomitant corticosteroid and ADT therapy of investigator choice/patient preference
Study: NCT06073327

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: dark chocolate
Description: 30g of dark or white chocolate was provided by the nutritionist for 30 days

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: White chocolate
Description: 30g of white chocolate was provided by the nutritionist for 30 days
Study: NCT05137262

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate
Description: Given by IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given by IV
Study: NCT06395168

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Combined Newborn and Lactation Visit
Description: See Arm/Group Description
Study: NCT05330611

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryoneurolysis of Intercostal Nerves
Description: Patients will be offered a minimally invasive intervention procedure for pain control called cryoneurolysis using an ultrasound-guided device called the Iovera Smart Tip 190.~The direct application of cold to the intercostal nerves via Iovera device produces lesions in peripheral nervous tissue to block the pain caused by rib fractures.~This procedure is particularly beneficial for patients who are not candidates for surgical stabilization of their rib fractures.~Application of cryoneurolysis as an analgesic will reduce the amount of narcotics patients might need and instead provide them short- or long-term pain control with minimal risk.~Follow up includes pain surveys administered in Chest Wall clinic or via telephone at 30, 90, 365 days post discharge.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Patients will be provided regular standard of care at the Stanford Hospital with short- or long-term follow-up provided at the Stanford Center for Reconstruction after Chest Wall Injury.~Standard of care for patients with rib fractures that are not eligible for surgical stabilization includes multi-modal pain therapy and pulmonary toilet.~Follow up includes pain surveys administered in Chest Wall clinic or via telephone at 30, 90, 365 days post discharge.
Study: NCT06538207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-4578
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-4578
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-4538
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-4538
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofolinate
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-Paclitaxel
Description: Specified dose on specified days
Study: NCT04444362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intestinal Microbiota Transplant (IMT) Capsules
Description: Intestinal Microbiota Transplant (IMT) Capsules tid immediately after cardiovascular surgery for at least 7 days
Study: NCT06464588

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Neonatal mesenchymal stromal cells (nMSCs)
Description: nMSCs will be administered intravenously in the predefined dose per each group. The rate of infusion will be approximately 30- 60 minutes at 0, 15 and 30 days, with escalating dose levels.
Study: NCT04897334

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: tDCS is a type of non-invasive brain stimulation in which small electrical currents are applied to the scalp via 2 electrodes. During sham stimulation, the current, 2 mA, will be delivered for a short amount of time and then turn-off. To deliver the current, electrodes that are placed in saline soaked sponges. They will be attached to the left side of your head; they will be held in place with an elastic cap. For both real and sham stimulation the electrodes will be placed on the scalp. Most people cannot tell the difference between real and sham stimulation.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tDCS
Description: tDCS is a type of non-invasive brain stimulation in which small electrical currents are applied to the scalp via 2 electrodes. During sham stimulation, the current, 2 mA, will be delivered for a short amount of time and then turn-off. To deliver the current, electrodes that are placed in saline soaked sponges. They will be attached to the left side of your head; they will be held in place with an elastic cap. For both real and sham stimulation the electrodes will be placed on the scalp. Most people cannot tell the difference between real and sham stimulation.
Study: NCT05750524

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: reflexology hand massage
Description: Reflexology massage methods applied randomly to both trial groups.
Study: NCT04897334

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Cognitive Therapy
Description: During both the treatment and the sham intervention, participants will undero cognitive therapy training by performing the NBack task. In this sequential letter memory exercise participants are presented with sequential stimuli in the form of a series of letters. For each new stimulus they are asked to indicate if the current stimulus matches the stimulus from 2 trials prior. This exercise stimulates cognitive demand in working memory, executive function and attention and is correlated with dorsolateral prefrontal cortex activity.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Therapy
Description: During both the treatment and the sham intervention, participants will undero cognitive therapy training by performing the NBack task. In this sequential letter memory exercise participants are presented with sequential stimuli in the form of a series of letters. For each new stimulus they are asked to indicate if the current stimulus matches the stimulus from 2 trials prior. This exercise stimulates cognitive demand in working memory, executive function and attention and is correlated with dorsolateral prefrontal cortex activity.
Study: NCT05750524

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: classical hand massage
Description: Classical hand massage methods applied randomly to both trial groups.
Study: NCT06563323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Subjects with PG will be treated with 100 mg in a pre-filled syringe to be injected subcutaneously every 4 weeks for 28 weeks.